Each point was worked out with the data available that day. Scale 0-10: 5 is the index average and 10 is the cap (+3 standard deviations), not perfection. The vertical axis zooms to fit this company, so two charts are not comparable by eye.
Market and Valuation
Price & Market
Prev Close Price:$93.26
Open:$93.67
Day's Low:$93.27
Day's High:$96.09
Bid / Ask:-
Market Cap:54.87B
Enterprise Value:50.31B
52-Week Range
52-Week Low:$74.66
52-Week High:$96.29
Current position in 52-week range
52w Low-52w High
50-Day Avg:$88.21
200-Day Avg:$85.47
Volume
Volume Today:6,525,904
Avg Volume (3m):3,465,453
Avg Volume (10d):4,220,580
52-Week Change:+10.83%
vs S&P 500, 52 weeks:-
Beta:0.83
Valuation Multiples
P/E (trailing):54.71
Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 4, 2026. The P/E is the price divided by that EPS.
P/E (forward):28.15
PEG Ratio:1.95
Price / Book:5.17
Price / Sales (TTM):8.43
EV / Revenue:7.73
EV / EBITDA:25.20
Dividends
Current yield:-
Annual Dividend Rate:-
Dividend Trailing:$0.00
Yield Trailing:0.00%
5-Year Avg Yield:-
Payout Ratio:0.00%
Last Ex-Dividend Date:-
Valuation Context
P/E vs sector (indicative)
Most Recent Quarter:-
Fiscal Year (Next):-
Loading historical OHLCV database...
Date
Open
High
Low
Close
Volume
Financial Statements TTM (Trailing 12 Months)
Income Statement
Total Revenue (TTM):6.51B
Gross Profit:5.07B
EBITDA:2.00B
Net Income (TTM):979.90M
Rev Growth (YoY):+13.60%
Earnings Growth (YoY):-25.40%
Quarterly earnings growth (YoY):-27.40%
Margins
Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-
Per Share
EPS Trailing (TTM):$1.74
Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 4, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$3.38
Revenue Per Share:$11.22
Cash Per Share:-
Book Value:$18.42
Last Dividend:-
Ex-Dividend Date:-
Last Split:-
Balance Sheet & Liquidity
Total cash:4.25B
Total Debt:704.40M
Net Debt (Debt - Cash):−3.55B (net cash)
Debt / Equity:6.57%
Current Ratio:4.52
Quick Ratio:3.45
Cash Flows
Operating Cash Flow:1.72B
Free Cash Flow (FCF):1.23B
FCF Yield (FCF / Market Cap):-
Enterprise Value:50.31B
EV / Revenue:7.73
EV / EBITDA:25.20
Profitability
ROE (Return on Equity):9.18%
ROA (Return on Assets):8.37%
P/E (trailing):54.71
P/E (forward):28.15
Price / Book:5.17
PEG Ratio:1.95
52-Week Change:+10.83%
S&P 500 change, 52 weeks:+11.37%
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
EPS Trailing (TTM):$1.74
Diluted EPS for the last 12 months: the four quarters ended Jun 30, 2026, from the accounts filed with the SEC on Aug 4, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$3.38
P/E (forward):28.15
PEG Ratio:1.95
Growth and Margins
Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-
Per Share
Revenue Per Share:$11.22
Cash Per Share:-
Book Value:$18.42
Cash Flows (TTM)
Free Cash Flow:1.23B
Operating Cash Flow:1.72B
EBITDA:2.00B
Total Revenue (TTM):6.51B
Net Income (TTM):979.90M
Fiscal Year (Last):-
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
Quarter
Period
Actual EPS
Estimated EPS
Difference
Surprise %
Currency
Ownership Structure
Ownership Distribution
% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float
Shares & Short Interest
Shares Outstanding:576,400,000
Float (free shares):574,693,856
Short interest (shares):9,333,399
Short % of float:-
Short Ratio (days to cover):2.43
Short interest, prior month:-
Short Interest Date:-
Governance Score (1=Best, 10=Worst)
Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
Organization
Report Date
% Shares
No. Shares
Value (USD)
Change %
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
Fund
Report Date
% Shares
No. Shares
Value (USD)
Change %
Recent Insider Trades
Executive / Insider
Title
Date
Action
Shares
Options Chain
CALLS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
PUTS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
Sentiment Metrics
Put/Call Ratio (Volume):-
Put/Call Ratio (O.I.):-
Max Pain (estimated):-
Total O.I. Calls:-
Total O.I. Puts:-
Expected move
Average IV (Calls ATM):-
Average IV (Puts ATM):-
Days to Expiration:-
Expected move (±):-
Edwards Lifesciences Corporation (EW) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Corporate Vice President of Strategy & Corporate Development
63
1.60M
Mr. Daveen Chopra
Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies
46
1.56M
Ms. Annette Maria Bruls
Corporate Vice President of EMEA, Canada, & Latin America
54
1.63M
Ms. Theodora Mistras
Corporate VP & CFO
43
-
Mr. Joseph Nuzzolese
Corporate Vice President of Global Operations & Quality
-
-
Mr. Andrew M. Dahl
Principal Accounting Officer, Senior VP & Corporate Controller
47
-
Dr. Todd Brinton FACC, M.D.
Corporate VP of Advanced Innovation & Technology and Chief Scientific Officer
-
-
You have seen the engine room
A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.
Edwards Lifesciences Corporation (EW) — Healthcare — Medical Devices. EW is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.
So far in 2026, EW has returned +11.7% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.
EW ranks 221 of 461 on today's multifactor score, and 29 of the 55 Healthcare companies that score. Its strongest factor is quality (Z 0.38, ranked 97 of 468); its weakest is value (Z -0.60, ranked 420 of 489). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.
Factor scores
The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.
Frequently asked questions about Edwards Lifesciences (EW)
When does Edwards Lifesciences report earnings?
According to Nasdaq's public calendar (checked on Nov 4, 2026), Edwards Lifesciences will report its next earnings on Nov 4, 2026, after the US market closes. The date is announced by the company itself and can change. Of its last 12 earnings announcements: 12 after the close (SEC filings through Jul 23, 2026). EW earnings dates and times, quarter by quarter →
What is Edwards Lifesciences's P/E ratio?
Edwards Lifesciences's P/E (price over earnings per share for the last twelve months) is 54.7 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Jun 30, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: Edwards Lifesciences is above its sector median. Healthcare stocks, company by company →
Where does Edwards Lifesciences rank on Quant500?
In the Nov 3, 2026 multi-factor ranking, Edwards Lifesciences ranks 221 of 461, and 29 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking →How it is calculated →
Have Edwards Lifesciences insiders bought or sold shares?
SEC Form 4 shows no open-market purchase of Edwards Lifesciences shares from August 2025 through Nov 3, 2026. The latest sale was on Oct 8, 2026, by an officer, for $53k. In total, from August 2025 through Nov 3, 2026: 0 purchases and 44 sales by directors, officers and large shareholders. All EW insider trades →
What sector is Edwards Lifesciences in, and which index?
Edwards Lifesciences is classified in the Healthcare sector (industry: Medical Devices), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →
What is behind these numbers
The concepts on this page, explained from scratch in the Academy. Free, no account.
Quality and low volatilityWhere the quality score comes from, and why it is the factor with the most competing definitions, all of them called the same thing.
We save the portfolios you design, your own portfolio and your Academy progress, synced across devices.
Free, no card. Two automatic emails and no more: the one that confirms your address and the welcome one. After that, nothing you do not switch on yourself in your profile — such as the alert for insider buys, the same day they are reported to the SEC.